Citations

Showing 10 of 108152 citations.

MO1037WOMEN REPRESENTATION IN CLINICAL PRACTICE GUIDELINES AMONG MAJOR NEPHROLOGY GUIDELINES
Mohan, Arjunmohan , Chengappa, Madhuri, Poonacha, Thejaswi , Herrmann, Sandra M.

Mayo Clinic

Nephrology Dialysis Transplantation | May 30, 2021 | Volume: 36 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfab109.004 Get It

Abstract Background and Aims While the percentage of women entering nephrology has increased over the years, women representation and sex disparities in the authorship of major nephrology Clinical practice guidelines (CPG) has not been examined. Our study evaluates current sex disparities and women representation, and the nationalities of women authors in nephrology CPGs developed by the Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Disease Outcomes Quality Initiative (KDOQI), and the European Renal Best Practice (ERBP), the official guideline body of the ERA-EDTA. Method We examined the number of female versus male guideline workgroup members (panelists) for all available CPGs in each of the three organizations as of Dec. 2020, which are available on their respective websites. We discerned the sex of the panelists based on google search and their affiliated institutional websites. We obtained the nationalities of the workgroup members from the authorship information of the respective CPG. Results Of the total 488 panelists in all three organizations, 115 (23.6%) were females and 373 (76.4%) males. KDIGO had 184 panelists, of which 46 (25%) were females. The CPGs with the highest and the least women representation are ‘Diabetes in Chronic Kidney Disease (CKD)’ (41.2%) and ‘Anemia in CKD’ (11.8%), respectively. The countries with the highest number of women representations are the USA (20), followed by Canada (6), and China (4). In KDOQI, 39 (31%) of 127 panelists were female. While CPGs related to ‘Evaluation and management of CKD’ and ‘Nutrition in children with CKD’ each had 50% female panelists, ‘Blood pressure management in CKD’ CPG had 10% female panelists. 28 (72%) of the total 39 women were from the USA. The ERBP had 30 (17%) females of the total 177 panelists. ‘CKD in older patients’ CPG comprised 42.1% female panelists. CPGs for ‘Glycemic control in diabetes’ and ‘Glucose lowering drugs in diabetes’ had no female panelists. Belgium and UK each had six women representatives, while France and The Netherlands 4 women representatives each. Conclusion The guidelines developed by the most prominent organizations – KDIGO, KDOQI, and ERA-EDTA have less than 25% women representation. While it is encouraging to note that there is more women representation in some of the CPGs developed by KDIGO in 2020, evaluating the barriers contributing to the under-representation of women in major nephrology organizations is warranted. Also notable is a lack of women representation from developing countries.
FC 013LUMASIRAN DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1
Shasha‐Lavsky, Hadas , Garrelfs, Sander F. , Sas, David J. , Ngo, Taylor , Makarova, Nune , Gansner, John M. , McGregor, Tracy L., Frishberg, Yaacov, Lieske, John C.

Mayo Clinic

Nephrology Dialysis Transplantation | May 30, 2021 | Volume: 36 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfab131.003 Get It

Abstract Background and Aims Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder characterized by hepatic overproduction of oxalate. Excretion of oxalate via the kidneys leads to recurrent kidney stones, nephrocalcinosis, progressive kidney disease, and multiorgan damage from systemic oxalosis. Lumasiran, a subcutaneously administered RNAi therapeutic indicated for the treatment of PH1 in all age groups, has multiple ongoing phase 3 studies including ILLUMINATE-A, which enrolled 39 patients ≥6 years of age with eGFR ≥30 mL/min/1.73m2, and ILLUMINATE-B, which enrolled 18 patients <6 years of age with eGFR >45 mL/min/1.73m2 if ≥12 months of age or normal serum creatinine if <12 months of age. Here we present a comparison of the efficacy and safety of lumasiran in children versus adults with PH1 using pooled data from these two phase 3 studies of lumasiran. Method Efficacy and safety data from ILLUMINATE-A and ILLUMINATE-B, including urinary oxalate, plasma oxalate, eGFR, and adverse events were pooled and assessed by age <18 (N=40), or ≥18 years old (N=17). The analysis included all available data from 57 patients with PH1, ages 4 months to 60 years, who completed the initial 6 months of treatment with lumasiran. Results During the initial 6 months of treatment with lumasiran, patients with PH1 had a rapid and sustained decrease in urinary oxalate. The overall mean (SEM) percent reduction in urinary oxalate:creatinine ratios as measured in random spot urine samples from baseline to Month 6 was 63.1% (2.6) across all ages (N=54). A similar time course and magnitude of reduction was seen in patients <18 years at 64.5% (3.3) (N=38), and ≥18 years old at 59.8% (4.4) (N=16). The oxalate reductions observed in random spot urine samples were comparable to those observed from 24-hour urine collections. The overall mean (SEM) percent reduction in urinary oxalate excretion from 24-hour collections was 63.8% (2.6) across all ages (N=40), 63.2% (3.5) in the <18 group (N=23) and 64.8% (3.9) in the ≥18 group (N=17). The overall mean (SEM) percent reduction in plasma oxalate from baseline to Month 6 was 39.5% (3.7) across all ages (N=44), with similar reductions of 39.4% (4.6) and 39.7% (6.5) in patients <18 (N=30) and ≥18 (N=14) years of age, respectively. eGFR was calculated for all patients ≥12 months of age and remained stable in both age groups during the 6 months of treatment with lumasiran. The 57 patients had a cumulative exposure of 27.1 patient-years and 227 doses were given. Adverse events were reported in 86% of all patients, 88% of patients <18, and 82% of patients ≥18 years of age. All adverse events were graded as mild or moderate in severity by the investigator. One patient had a serious adverse event of viral infection that was not related to lumasiran. In all patients, the most common adverse events related to lumasiran were mild, transient, injection site reactions, experienced by 30% of all patients, 23% of patients <18 and 47% of patients ≥18 years of age. No treatment interruptions or discontinuations related to lumasiran or deaths occurred. Conclusion Lumasiran reduced urinary and plasma oxalate to a similar degree in pediatric and adult patients with PH1 enrolled in the Phase 3 studies ILLUMINATE-A and ILLUMINATE-B. Reductions in urinary oxalate were similar between random spot urine samples and valid 24-hour urine collections. Overall safety was comparable between pediatric and adult patients.
MO021ENHANCED MCP-1 RELEASE IN EARLY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Decuypere, Jean-Paul , Breysem, Luc , Giel, Dorien Van , Billen, Jaak, Hindryckx, An , Janssens, Peter , Rechter, Stéphanie De , Billen, Jaak, Catte, Luc De , Baldewijns, Marcella M.L.L. , Claes, Kathleen , Wissing, Karl Martin , Devriendt, Koenraad , Bammens, Bert , Meyts, Isabelle , Torres, Vicente E. , Vennekens, Rudi , Mekahli, Djalila

Mayo Clinic

Nephrology Dialysis Transplantation | May 30, 2021 | Volume: 36 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfab081.003 Get It

Abstract Background and Aims Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in either the PKD1 or PKD2 gene. While kidney failure typically occurs in adulthood, the disease starts in utero. The best change of preserving renal function long term might be the use of agents with few side effects as early as possible. For this approach, both better early prognostic stratification and novel treatment options are needed. The pediatric phase of ADPKD, while kidney function is still normal and before significant tissue destruction has occurred could be the best stage both to identify and study prognostic biomarkers as well as to identify novel targets for early treatment. Copeptin (a surrogate for vasopressin), epidermal growth factor (EGF) ( a measure for functional tubular mass) and monocyte chemoattractant protein-1 (MCP-1) ( a chemoattractant for macrophages) are associated with severity and hold prognostic value in adults but remain unstudied in the early disease stage. Kidneys from adults with ADPKD exhibit macrophage infiltration, and a prominent role of MCP-1 secretion by tubular epithelial cells is suggested from rodent models. Method A monocentric cross-sectional study in a tertiary referral center was performed. All consenting genotyped ADPKD patients attending the outpatient pediatric ADPKD clinic of the university hospital of Leuven and age, sex and BMI matched healthy controls were included between June and October 2017. Plasma copeptin, urinary EGF and urinary MCP-1 were evaluated. MCP-1 was studied in mouse collecting duct cells, human proximal tubular cells and fetal kidney tissue. Results 53 genotyped ADPKD patients and 53 controls were included. Mean (SD) age was 10.4 (5.9) vs 10.5 (6.1) years (P=0.543), and eGFR 122.7 (39.8) vs 114.5 (23.1) ml/min/1.73 m2 (P= 0.177) in patients vs controls respectively. Outcome parameters in table. Plasma copeptin and EGF secretion were comparable between both groups. Median (IQR) urinary MCP-1 (pg/mg creatinine) was significantly higher in ADPKD patients (185.4 (213.8)) compared to controls (154.7 (98.0)) (P= 0.010). Human proximal tubular cells with a heterozygous PKD1 mutation and mouse collecting duct cells with a PKD1 knockout exhibited increased MCP-1 secretion triggered by fetal bovine serum. Human fetal ADPKD kidneys displayed prominent MCP-1 immunoreactivity and M2 macrophage infiltration. Conclusion An increase in tubular MCP-1 secretion is an early event in ADPKD, long before kidney function decline and in children with few kidney cysts. MCP-1 is a promising early disease severity marker and a potential treatment target.
MO047STABLE EGFR IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 TREATED WITH LUMASIRAN, REGARDLESS OF KIDNEY FUNCTION AT START OF TREATMENT
Garrelfs, Sander F. , Sas, David J. , Ngo, Taylor , Gansner, John M. , McGregor, Tracy L., Frishberg, Yaacov, Hayes, Wesley Nathan , Lieske, John C.

Mayo Clinic

Nephrology Dialysis Transplantation | May 30, 2021 | Volume: 36 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfab080.0019 Get It

Abstract Background and Aims Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder characterized by hepatic oxalate overproduction. Excess oxalate is excreted by the kidneys, leading to recurrent kidney stones, nephrocalcinosis, and progressive kidney disease. Patients with PH1 generally experience a slow decline in kidney function over time that can be punctuated by abrupt worsening precipitated by infection, obstructing stones, or dehydration. Approximately half of patients with PH1 progress to kidney failure by early adulthood, and nearly all by 60 years of age. Lumasiran is an RNAi therapeutic indicated for the treatment of PH1 in all age groups. In clinical trials, treatment with lumasiran resulted in substantial reductions in urinary and plasma oxalate in pediatric and adult patients, with an acceptable safety profile. This analysis evaluates the change in kidney function of patients with PH1 with an eGFR of ≥30 mL/min/1.73m2 enrolled in clinical trials of lumasiran. Method We analyzed kidney function from 75 patients with PH1, age ≥12 months old, eGFR ≥30 mL/min/1.73m2, enrolled in 3 clinical trials of lumasiran (Phase 2 open-label extension, and Phase 3 ILLUMINATE-A and ILLUMINATE-B). In these trials, eGFR was calculated with the Modification of Diet in Renal Disease (MDRD) Study equation in adults or the bedside Schwartz equation in children. The effect of lumasiran on eGFR was assessed by baseline eGFR subgroup: ≥90, <90, 60 to <90, 45 to <60, and 30 to <45 mL/min/1.73m2. Results Of 75 patients available for analysis, 46 were treated with lumasiran from the start of the study through the Month 12 visit. eGFR remained stable in all eGFR subgroups. Patients with eGFR ≥90 mL/min/1.73m2 at baseline (N=16) demonstrated fluctuations in mean values by timepoint, with a mean change (95% CI) from baseline of -1 (-8, 6) mL/min/1.73m2 at Month 12. In patients with eGFR <90 mL/min/1.73m2 (N=30), no change in mean eGFR from baseline was observed at Month 12; the mean change (95% CI) was 0 (-3, 3). When evaluating subgroups with impaired kidney function, variations in the mean change were observed at Month 12 due to small sample sizes. For patients with eGFR 60 to <90 mL/min/1.73m2 (N=22), the mean change (95% CI) was -2 (-5, 1). For patients with eGFR 45 to <60 mL/min/1.73m2 (N=5), the mean change (95% CI) was 3 (-8, 14). For patients with eGFR 30 to <45 mL/min/1.73m2 (N=3), the mean change (95% CI) was 9 (7, 11). Conclusion Patients with PH1 had stable kidney function over time with lumasiran treatment, regardless of kidney function at baseline. Given the progressive kidney function decline that is characteristic of PH1, the eGFR stability observed during 12 months of treatment with lumasiran is encouraging. Kidney function will continue to be monitored for the duration of the lumasiran clinical trials.
MO769COMPARISON OF HEMODIALYSIS CONNECTORS CAPS VS ANTIMICROIAL BARRIER CAPS IN CENTERAL LINE-ASSOICATED BLOOSTREAM INFECTION RATES FOR HEMODIALYSIS PATIENTS
Hemeyer, Connie J., Moreland, Marshall, Olson, Elsa , Fitzpatrick, Peter M., Olson, Elsa, Hickson, LaTonya J.

Mayo Clinic

Nephrology Dialysis Transplantation | May 30, 2021 | Volume: 36 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfab103.007 Get It

Abstract Background and Aims Central line-associated bloodstream infections (CLABSI) lead to increased morbidity and mortality in hemodialysis-dependent patients and are costly to treat. Devices such as hemodialysis connector caps (Tego) and antimicrobial barrier caps (ClearGuardHD) represent promising interventions to reduce CLABSIs. The aim of this study was to assess the efficacy of these devices in reducing CLABSIs in hemodialysis patients who use tunneled dialysis catheters at outpatient dialysis units in a healthcare system. Method In a retrospective review of a quality improvement project, we compared cumulative 6-month CLABSI infection rates before and after transition from Tego connectors to ClearGuardHD caps. CLABSI events, reported to National Healthcare Safety Network (NHSN), were expressed as CLABSI events per 100 patient-months. All adult patients (age >18 years) receiving hemodialysis via a tunneled central catheter were included in the study from February 2018-August 2020. The study cohort was comprised of 13 outpatient dialysis units in a healthcare system with locations throughout the Northern Midwest and Southeastern United States. The date of change from Tego to ClearGuardHD was phased throughout the different units over the study period with events recorded 6 months pre- and post-intervention. Patients receiving home dialysis therapies were excluded from the study. Results The cumulative 6-month CLABSI event rate decreased by 75.7%; Tego (0.465/100 patient-months) vs. ClearGuardHD caps (0.113/100 patient-months). A total of 17 CLABSI occurrences were reported within 3,654 patient-months with Tego use. However, only 4 CLABSI occurrences were reported within 3,527 patient-months during ClearGuardHD use. Conclusion ClearGuardHD caps reduced the rate of CLABSI among hemodialysis patients and are superior to Tego connectors. These findings support prior studies. Implementation of ClearGuardHD caps may help eliminate CLABSI-associated morbidity among individuals requiring maintenance hemodialysis therapy.
MO075KLF11 DEFICIENCY ENHANCES CHEMOKINE GENERATION AND INJURY IN MURINE UNILATERAL URETERIC OBSTRUCTION
DeLorenzo, Silvana, Grande, Joseph P.

Mayo Clinic

Nephrology Dialysis Transplantation | May 30, 2021 | Volume: 36 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfab078.0011 Get It

Abstract Background and Aims Kruppel-like factors (KLFs) comprise a family of zinc-finger transcription factors that play a critical role in development, proliferation, and regeneration following injury. There are over 17 members of this family; recent studies have shown that KLF family members regulate podocyte differentiation, preservation of the glomerular filtration barrier, and regulation of mitochondrial function. However, a role for KLF11 in renal pathophysiology has not been previously established. Method Wild-type (WT) and KLF11 knockout (KO) mice were subjected to unilateral ureteric obstruction (UUO), a well-established model of renal inflammation and fibrosis; controls included mice subjected to manipulation of the ureter without ligation. Kidneys were harvested after 9 days (n=8 animals per group). Semiquantitative histopathologic analysis of renal atrophy, fibrosis, and inflammation was performed in a blinded fashion. Gene expression analysis was performed on renal cortex employing the Pathway Detect RNA array and RNASeq. Results In UUO, renal atrophy was more severe in KLF11 KO mice than WT mice (p<0.001). Deposition of collagen, as assessed by quantitative analysis of Sirus Red stained sections, was greater in KLF11 KO mice, compared to WT mice subjected to UUO; COL3A1 expression was also increased (p<0.05). Atrophy was associated with an increase in F4/80+ (p<0.01) and CD206+ macrophages (p<0.05), but not CD3+ T cells in KLF11 KO vs. WT mice. Induction of CC chemokines, including CCL2, CCL5, CCL7, CCL12, and CCL2 as well as CCR2 was significantly higher in KLF11 KO versus WT mice subjected to UUO (all p<0.001). Expression of NF-kB (p<0.01) and TNF alpha (p<0.01), but not IL-1 beta, IL-6, or IL-10 were significantly higher in KLF11 KO than WT mice with UUO. Expression of TGF-beta 1, Smad2, and Smad3 were also higher in KLF11 KO mice than WT mice with UUO (p<0.05). Conclusion Renal injury in UUO is exacerbated in KLF11 KO mice, compared to WT mice. Injury is associated with increased macrophage influx and production of pro-inflammatory chemokines. Future studies will determine how KLF11 deficiency directs transcription of pro-inflammatory and pro-fibrotic genes.
A Polymorphic Multigene Family Encoding an Immunodominant Protein from Babesia microti
Homer, Mary J., Bruinsma, Elizabeth S. , Lodes, Michael J., Telford, Samuel R., Krause, Peter J. , Reynolds, Lisa D., Mohamath, Raodoh, Benson, Darin R., Houghton, Raymond L., Reed, Steven G. , Persing, David H., Moro, Matteo

Mayo Clinic

Journal of Clinical Microbiology | May 29, 2021 | Volume: 38 | Issue: 1 | Pages: 362-368

10.1128/jcm.38.1.362-368.2000 | PMID 10618117 Get It

ABSTRACT Human babesiosis in the United States is caused predominantly by Babesia microti , a tick-transmitted blood parasite. Improved testing methods for the detection of infection with this parasite are needed, since asymptomatic B. microti infection represents a potential threat to the blood supply in areas where B. microti is endemic. We performed immunoscreening of an expression library of genomic DNA from a human isolate of B. microti (strain MN1). Among 17 unique immunoreactive clones, we identified 9 which represent a related family of genes with little sequence homology to other known sequences but with an architecture resembling that of several surface proteins of Plasmodium . Within this family, a tandem array of a degenerate six-amino-acid repeat (SEAGGP, SEAGWP, SGTGWP, SGTVGP) was found in various lengths between relatively well conserved segments at the N and C termini. In order to examine within-clone variation, we developed a PCR protocol for direct recovery of a specific bmn1-6 homologue directly from 30 human blood isolates, 4 corresponding hamster isolates, and 5 geographically corresponding Peromyscus leucopus (white-footed mouse) isolates. Isolates from the hamsters had the same sequences as those found in the corresponding human blood, suggesting that genetic variation of bmn1-6 does not occur during passage. However, clones from different patients were often substantially different from each other with regard to the number and location of the degenerate repeats within the bmn1-6 homologue. Moreover, we found that strains that were closely related geographically were also closely related at the sequence level; nine patients, all from Nantucket Island, Mass., harbored clones that were indistinguishable from each other but that were distinct from those found in other northeastern or upper midwestern strains. We conclude that considerable genetic and antigenic diversity exists among isolates of B. microti from the United States and that geographic clustering of subtypes may exist. The nature of the bmn1-6 gene family suggests a mechanism of antigenic variation in B. microti that may occur by recombination, differential expression, or a combination of both mechanisms.
Role of Genotypic Analysis of the Thymidine Kinase Gene of Herpes Simplex Virus for Determination of Neurovirulence and Resistance to Acyclovir
Lee, N. Y., Espy, Mark J., Kolbert, Christopher P., Rys, Paul N., Mitchell, P. Shawn, Day, S. P., Henry, S. L., Persing, D. H., Smith, T. F., Tang, Yi‐Wei , Henry, Semakula, Smith, T. F.

Mayo Clinic

Journal of Clinical Microbiology | May 29, 2021 | Volume: 38 | Issue: 3 | Pages: 1311-1311

10.1128/jcm.38.3.1311a-1311a.2000 Get It

Acute thrombosis of a giant perimedullary arteriovenous fistula in a pediatric HHT patient
Devara, Janaki , Brinjikji, Waleed , Aljobeh, Ahmad , Demirel, Nadir , Brinjikji, Waleed , Demirel, Nadir , Iyer, Vivek , Warad, Deepti , Lanzino, Giuseppe

Mayo Clinic

Interventional Neuroradiology | May 29, 2021 | Volume: 28 | Issue: 2 | Pages: 132-135

10.1177/15910199211022499 | PMID 34053318 Get It

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant hereditary disorder that results in arteriovenous malformations (AVMs) in the nose, mucocutaneous surfaces and visceral organs, including lung, brain, liver, bowel and rarely spinal cord. We describe a case of a young child with HHT who presented with acute paraparesis due to acute thrombosis of a spinal perimedullary arteriovenous fistula. Patient underwent coil embolization of spinal arteriovenous shunt with resolution of clinical symptoms. This case highlights the possibility of catastrophic complications in young children with HHT, the potential preventive role of screening for spinal AVMs in HHT and the importance of timely intervention.
Editor-in-Chief transition: Looking ahead
Brinjikji, Waleed

Mayo Clinic

The Neuroradiology Journal | May 29, 2021 | Volume: 34 | Issue: 3 | Pages: 153-153

10.1177/19714009211011559 | PMID 34039113 Get It